they express T-type calcium channels. The little cells also have slower calcium transients and a lower density of transient outward current than the big cells, reminiscent of the cardinal pathophysiological changes associated with myocytes isolated from patients or animals with heart failure. 6 -11 In vitro evidence is discussed, but not presented in full, to the effect that c-kit ϩ CSCs isolated from the cat heart can become little myocytes when cocultured with neonatal rat heart cells (Tom and Jerry take note). Little cells are more often Brdu ϩ and have a somewhat higher telomerase activity than big cells, suggesting that they are more proliferative. Thus, the little cells presumably are newly-hatched myocytes, the missing links between CSCs and mature heart cells. Read the article. There is more, including a critical calculation arguing that postnatal growth of the heart is due largely to myocyte proliferation, not just myocyte hypertrophy.
As with all groundbreaking articles, more questions arise than are answered. Missing here is evidence of new vascular cells arising endogenously within the heart, or from c-kit ϩ cells in culture; also lacking is any evidence that little cells actually go on to become big cells. Might they be in a state of arrested development? It is curious and counterintuitive that the percentage of little cells is identical and fairly high (11.5%) at 11 weeks and 22 weeks, despite the fact that the heart doubles in size over that interval. If CSCs produce little cells which go on to become big cells, one might conjecture that the proportion of little cells would fall over time to some asymptotic frequency at which the creation of new cells just offsets the very low rate of apoptosis (quantified at only 0.08% in the present work). Perhaps the 22 week time point studied here is still far from the steady state that would be reached in mid-adulthood.
The recognition that the heart is not static but rather sustains turnover and self-repair has opened up dramatic new possibilities for therapeutics. If the heart has the capacity to renew itself, perhaps that capacity can be tapped to achieve iatrogenic regeneration, in those cases where catastrophic events such as myocardial infarction have outstripped the heart's endogenous repair capacity. Methods have already been developed to harvest stem cells from a patient's own heart using minimally-invasive methods; millions of transplantable cells can be grown in vitro, creating a very specific paradigm for autologous therapeutics. 12 Soon we may be able to grow "little cells" from transplanted CSCs within the diseased human heart, with a view to restoring functional capacity.
Take a minute to catch your breath. Never has cardiobiology been more exciting than it is now.
